Atyr PHARMA INC (NASDAQ:ATYR) Receives $18.60 Consensus Target Price from Brokerages

Atyr PHARMA INC (NASDAQ:ATYR) has received an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $18.60.

Several analysts have recently issued reports on ATYR shares. Leerink Partners started coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective for the company. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday, March 14th. Finally, Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating for the company.

Hedge Funds Weigh In On Atyr PHARMA

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its holdings in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after buying an additional 10,754 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new position in Atyr PHARMA in the 4th quarter worth $170,000. Alterna Wealth Management Inc. acquired a new position in Atyr PHARMA in the 4th quarter worth $36,000. D.A. Davidson & CO. acquired a new position in Atyr PHARMA in the 4th quarter worth $141,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Atyr PHARMA in the 4th quarter worth $144,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Stock Down 0.8 %

ATYR stock opened at $3.84 on Friday. The stock has a market capitalization of $322.34 million, a P/E ratio of -4.09 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a one year low of $1.42 and a one year high of $4.66. The company has a 50 day moving average price of $3.66 and a two-hundred day moving average price of $3.11.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, sell-side analysts expect that Atyr PHARMA will post -0.91 EPS for the current year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.